Tideglusib treatment also decreased levels of beta-secretase 1 (BACE-1) and phospho-tau in cerebral spinal fluid of Alzheimer’s disease patients (Lovestone et al., 2015). This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.